Valletti Alessio, Gigante Margherita, Palumbo Orazio, Carella Massimo, Divella Chiara, Sbisà Elisabetta, Tullo Apollonia, Picardi Ernesto, D'Erchia Anna Maria, Battaglia Michele, Gesualdo Loreto, Pesole Graziano, Ranieri Elena
Institute of Biomembranes and Bioenergetics, CNR, Bari, Italy.
PLoS One. 2013 Oct 23;8(10):e78452. doi: 10.1371/journal.pone.0078452. eCollection 2013.
Clear cell renal cell carcinoma (ccRCC) is the most common malignant renal epithelial tumor and also the most deadly. To identify molecular changes occurring in ccRCC, in the present study we performed a genome wide analysis of its entire complement of mRNAs. Gene and exon-level analyses were carried out by means of the Affymetrix Exon Array platform. To achieve a reliable detection of differentially expressed cassette exons we implemented a novel methodology that considered contiguous combinations of exon triplets and candidate differentially expressed cassette exons were identified when the expression level was significantly different only in the central exon of the triplet. More detailed analyses were performed for selected genes using quantitative RT-PCR and confocal laser scanning microscopy. Our analysis detected over 2,000 differentially expressed genes, and about 250 genes alternatively spliced and showed differential inclusion of specific cassette exons comparing tumor and non-tumoral tissues. We demonstrated the presence in ccRCC of an altered expression of the PTP4A3, LAMA4, KCNJ1 and TCF21 genes (at both transcript and protein level). Furthermore, we confirmed, at the mRNA level, the involvement of CAV2 and SFRP genes that have previously been identified. At exon level, among potential candidates we validated a differentially included cassette exon in DAB2 gene with a significant increase of DAB2 p96 splice variant as compared to the p67 isoform. Based on the results obtained, and their robustness according to both statistical analysis and literature surveys, we believe that a combination of gene/isoform expression signature may remarkably contribute, after suitable validation, to a more effective and reliable definition of molecular biomarkers for ccRCC early diagnosis, prognosis and prediction of therapeutic response.
透明细胞肾细胞癌(ccRCC)是最常见的恶性肾上皮肿瘤,也是最致命的。为了识别ccRCC中发生的分子变化,在本研究中,我们对其全部mRNA进行了全基因组分析。基因和外显子水平的分析通过Affymetrix外显子阵列平台进行。为了可靠地检测差异表达的可变剪接外显子,我们实施了一种新方法,该方法考虑外显子三联体的连续组合,当表达水平仅在三联体的中央外显子中有显著差异时,识别候选差异表达的可变剪接外显子。使用定量RT-PCR和共聚焦激光扫描显微镜对选定基因进行了更详细的分析。我们的分析检测到2000多个差异表达基因,约250个基因发生可变剪接,并且在肿瘤组织和非肿瘤组织中显示出特定可变剪接外显子的差异包含。我们证明了PTP4A3、LAMA4、KCNJ1和TCF21基因在ccRCC中存在表达改变(在转录本和蛋白质水平)。此外,我们在mRNA水平上证实了先前已鉴定的CAV2和SFRP基因的参与。在外显子水平上,在潜在候选基因中,我们验证了DAB2基因中一个差异包含的可变剪接外显子,与p67异构体相比,DAB2 p96剪接变体显著增加。基于所获得的结果及其在统计分析和文献调查方面的稳健性,我们认为,经过适当验证后,基因/异构体表达特征的组合可能会显著有助于更有效和可靠地定义用于ccRCC早期诊断、预后和治疗反应预测的分子生物标志物。